WUNDER-MOBILITY
29.10.2021 08:32:05 CEST | Business Wire | Press release
Wunder Mobility , the international provider of software and hardware for new mobility services, has launched its first co-developed e-bike. Unveiled at the Wunder Mobility Summit 2021, the new bike has been designed in partnership with Yadea , specifically for shared use. It boasts an industry-topping range of 120km, comes with a speed of 25 km/h, and is specifically designed for European markets.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211028006347/en/
The e-bike’s launch follows the recent IPCC Intergovernmental Panel on Climate Change Sixth Assessment Report which drastically shows that CO2 emissions must be substantially reduced.
As an environmentally friendly mode of transport, bike-sharing is expected to grow 11% worldwide by 2025 . During COVID-19, spurred on by booming consumer demand, many city authorities have increased their efforts to make their cities more bike-friendly. Initiatives include pop-up lanes and new cycleways. Political commitments to a transition to the Green Economy continue to drive investment in cycling infrastructure.
Working with Yadea, the world’s largest manufacturer of electric two-wheel vehicles, Wunder Mobility's own e-bike is a leap forward in design to help shared mobility operators capitalise on increasing opportunity. The companies are building on their long-standing relationship with Wunder Mobility’s software integrating with Yadea vehicles since 2019.
Taking shared e-bike performance to the next level
This is the first time an e-bike has been co-designed with Wunder Mobility’s technology and insight at its core. It combines Wunder Mobility’s data-driven understanding of the needs of operators and their users with Yadea’s market leadership in design and manufacturing.
With a range of 120km the e-bike far exceeds the industry average of 70-80km and is based on rider biometrics which best fit the European market. It is equipped with a motor lock and a smart lock for dual security – a rear wheel cover enclosing the locking mechanism to prevent tampering and offering space for marketing purposes. A swappable battery, firmware updates over the air and a built-in IoT connector which comes with Wunder Mobility software provide further ease of use for operators.
Gunnar Froh, Founder and Chief Executive Officer of Wunder Mobility
, said:
“Cycling is one of the key solutions for reducing mobility emissions. Through our collaboration we have produced a better performing e-bike for both the operator and the cyclist. This will play a vital role in helping cities and their citizens to achieve green goals and boost wellbeing through exercise. Superior range, weight and security coupled to our powerful platform will enable more short city journeys and cleaner and healthier longer distance urban travel.”
Heidi Zang, Overseas Director at Yadea
,
said:
“The extensive market research, analysis and design development behind this e-bike has deepened our close collaboration with the team at Wunder Mobility. A market-dominating high range, low weight and uncomplicated maintenance sets new standards and complements the product portfolio of environmentally friendly urban mobility solutions. The simple and smooth design is unique in the sharing field, attracting consumers' attention and encouraging them to choose this e-bike.”
ENDS
Yadea:
Yadea is a global leader in developing and manufacturing electric two-wheel vehicles including electric motorcycles, electric mopeds, electric bicycles and electric kick scooters. Yadea's mission is to use its market leadership to inspire a movement towards greener travel solutions and its vision is to create world-leading electric vehicle solutions by building innovative technologies that meet and exceed international standards for safety and quality.
For more information: www.yadea.com
.
Wunder Mobility:
Wunder Mobility is the global leader in software and hardware for new mobility services. The mobility tech company provides white-label solutions that enable enterprises, startups and cities worldwide to deliver sustainable, convenient and secure mobility.
100+ customers in over 900 cities on six continents use the Wunder Mobility platform to launch and scale new mobility services, manage and finance shared vehicle fleets, optimize daily operations, and improve urban planning and traffic management.
The global Wunder Mobility team, with more than 40 nationalities, consists of technology and mobility industry veterans. 50% of the team is in Product and Engineering. Wunder Mobility was founded in 2014 by Gunnar Froh and Sam Baker. The headquarters are in Hamburg, with additional locations in Dortmund and Los Angeles. For more information:
www.wundermobility.com
| LinkedIn
| Twitter
| YouTube
| Wunder Mobility Podcast
View source version on businesswire.com: https://www.businesswire.com/news/home/20211028006347/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse
Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release
Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
